In this recent study by Srivastava et al., the authors follow in this tradition and suggest a novel therapeutic strategy for T-cell acute lymphoblastic leukemia (T-ALL) focused on disrupting the nucleotide synthesis pathway by targeting the ubiquitin protein ligase E3 component N-recognin 7 (UBR7)4. This evidence concerns the gene UBR7 and acute lymphoblastic leukemia.